e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch, Vincent Cottin
Source:
Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020
Journal Issue:
February
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch, Vincent Cottin. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
The new challenge of CTD-ILD: from basic science to clinical setting
Time to breathe: How COVID-19 interacts with interstitial lung disease
Related content which might interest you:
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021
Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Source: International Congress 2016 – Orphan diseases II
Year: 2016
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021
Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study.
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry
Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases
Year: 2020
Treatment dilemmas in sarcoidosis - a retrospective cohort study
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Measuring patient activation in an interstitial lung disease (ILD) population: an exploratory study
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept